![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: C6orf226 |
Gene summary for C6ORF226 |
![]() |
Gene information | Species | Human | Gene symbol | C6orf226 | Gene ID | 441150 |
Gene name | chromosome 6 open reading frame 226 | |
Gene Alias | C6orf226 | |
Cytomap | 6p21.1 | |
Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q5I0X4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
441150 | C6orf226 | C06 | Human | Oral cavity | OSCC | 1.53e-02 | 7.05e-01 | 0.2699 |
441150 | C6orf226 | C07 | Human | Oral cavity | OSCC | 2.05e-04 | 6.92e-01 | 0.2491 |
441150 | C6orf226 | C08 | Human | Oral cavity | OSCC | 1.71e-30 | 6.61e-01 | 0.1919 |
441150 | C6orf226 | C09 | Human | Oral cavity | OSCC | 4.45e-04 | 2.09e-01 | 0.1431 |
441150 | C6orf226 | LN22 | Human | Oral cavity | OSCC | 4.81e-06 | 6.92e-01 | 0.1733 |
441150 | C6orf226 | LN46 | Human | Oral cavity | OSCC | 1.03e-05 | 3.47e-01 | 0.1666 |
441150 | C6orf226 | LP15 | Human | Oral cavity | LP | 1.39e-05 | 7.33e-01 | 0.2174 |
441150 | C6orf226 | SYSMH1 | Human | Oral cavity | OSCC | 1.36e-17 | 4.30e-01 | 0.1127 |
441150 | C6orf226 | SYSMH2 | Human | Oral cavity | OSCC | 1.37e-10 | 3.09e-01 | 0.2326 |
441150 | C6orf226 | SYSMH3 | Human | Oral cavity | OSCC | 5.85e-09 | 2.77e-01 | 0.2442 |
441150 | C6orf226 | SYSMH4 | Human | Oral cavity | OSCC | 3.70e-02 | 7.85e-02 | 0.1226 |
441150 | C6orf226 | SYSMH5 | Human | Oral cavity | OSCC | 8.27e-04 | 1.17e-01 | 0.0647 |
441150 | C6orf226 | SYSMH6 | Human | Oral cavity | OSCC | 2.10e-08 | 2.17e-01 | 0.1275 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C6orf226 | SNV | Missense_Mutation | novel | c.47N>T | p.Ser16Leu | p.S16L | Q5I0X4 | protein_coding | deleterious_low_confidence(0.04) | benign(0.022) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C6orf226 | SNV | Missense_Mutation | novel | c.104N>T | p.Pro35Leu | p.P35L | Q5I0X4 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-EO-A3AZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C6orf226 | SNV | Missense_Mutation | c.101N>C | p.Leu34Pro | p.L34P | Q5I0X4 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.873) | TCGA-MI-A75C-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
C6orf226 | SNV | Missense_Mutation | c.41C>G | p.Ser14Cys | p.S14C | Q5I0X4 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.505) | TCGA-91-6840-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
C6orf226 | SNV | Missense_Mutation | novel | c.262N>A | p.Glu88Lys | p.E88K | Q5I0X4 | protein_coding | tolerated_low_confidence(0.16) | benign(0.003) | TCGA-96-A4JL-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | gemzar | CR |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |